How the bio revolution could transform the competitive landscape

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<rdf:Description>
<dc:creator>Chui, Michael </dc:creator>
<dc:creator>Evers, Matthias</dc:creator>
<dc:creator>Zheng, Alice </dc:creator>
<dc:creator>McKinsey & Company</dc:creator>
<dc:date>2020-05-01</dc:date>
<dc:description xml:lang="es">Sumario: Fueled by breakthroughs in biological science and the confluence of exponential advances in data, analytics, and digitization, what until recently might have read like a page out of a science fiction novel is becoming a reality. Moreover, biological innovations have been deployed to aid in the response to COVID-19, allowing for faster identification of the virus, more effective diagnostics, and new bioengineered treatments.1 The wide-ranging implications for business executives should go well beyond the obvious and expected. </dc:description>
<dc:identifier>https://documentacion.fundacionmapfre.org/documentacion/publico/es/bib/171676.do</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>McKinsey & Company</dc:publisher>
<dc:rights xml:lang="es">InC - http://rightsstatements.org/vocab/InC/1.0/</dc:rights>
<dc:subject xml:lang="es">COVID-19</dc:subject>
<dc:subject xml:lang="es">Coronavirus</dc:subject>
<dc:subject xml:lang="es">Pandemias</dc:subject>
<dc:subject xml:lang="es">Biotecnología</dc:subject>
<dc:subject xml:lang="es">Digitalización</dc:subject>
<dc:subject xml:lang="es">Biomedicina</dc:subject>
<dc:subject xml:lang="es">Biomecánica</dc:subject>
<dc:subject xml:lang="es">Transformación digital</dc:subject>
<dc:type xml:lang="es">Livros</dc:type>
<dc:title xml:lang="es">How the bio revolution could transform the competitive landscape</dc:title>
<dc:format xml:lang="es">10 p.</dc:format>
</rdf:Description>
</rdf:RDF>